Table 4.
Costs over the 12 months before the enrolment and at the end of the following 12 months in the overall sample (€/patient/year)
| Baseline | After 12 months | Difference | p | |
|---|---|---|---|---|
| Hospitalization | 218.06 (±29.02) | 104.37 (±18.44) | −113.69 (±28.69) | < 0.001 |
| GP visits | 13.09 (±0.88) | 5.06 (±0.42) | −8.03 (±0.91) | < 0.001 |
| Specialist visit | 18.18 (±0.89) | 20.23 (±0.77) | 2.05 (±1.16) | < 0.001 |
| Rescue medication | 19.19 (±1.41) | 13.39 (±1.19) | −5.80 (±1.70) | < 0.001 |
| Concomitant therapies | 50.65 (±4.34) | 60.20 (±4.90) | 9.55 (±2.84) | ns |
| Respiratory therapies | 636.68 (±19.87) | 851.30 (±23.88) | 214.62 (±21.55) | < 0.001 |
| DIRECT COSTS | 955.85 (±41.37) | 1,054.56 (±37.20) | 98.71 (±41.91) | < 0.001 |
| Days of inactivity | 227.29 (±42.59) | 236.34 (±44.58) | 9.05 (±50.88) | ns |
| INDIRECT COSTS | 227.29 (±42.59) | 236.34 (±44.58) | 9.05 (±50.88) | ns |
| TOTAL COSTS | 1,183.14 (±65.79) | 1,290.89 (±68.74) | 107.76 (±71.62) | < 0.001 |
Mean (±SE, standard error); GP: general practitioner
p values refer to Wilcoxon rank-sum test; ns: not significant